Publication | Closed Access

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis1Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc.1

Cerebrospinal Fluid AbnormalitiesNeurodegenerative DiseasesMultiple Sclerosis1studiesNeurobiology Of DiseaseNeurological DisorderMedicineNeuroepidemiologyCerebrospinal FluidPhase Iii TrialClinical NeurologyNeurological MonitoringNeuroscienceNeurologyMultiple SclerosisCerebral Blood FlowNeuroimmunologyNeurological AssessmentSocial Sciences